Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Inclusion Criteria

• •Patients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal disease (Turnstile I)
• •Patients must have a lesion amenable to resection for the generation of TIL (Turnstile I)
• •Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
• •Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 within 30 days of signing informed consent (Turnstile I)
• •Patients previously treated with immunotherapy, targeted therapy, or no therapy will be eligible; patients receiving cytotoxic agents will be evaluated by the PI or his designee
• •Patients with a negative pregnancy test (urine or serum) must be documented within 14 days of screening for women of childbearing potential (WOCBP); a WOCBP has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 12 consecutive months (Turnstile I)
• •Patients must have adequate TIL available (Turnstile II)
• •Patients must have at least one biopsiable and measurable metastatic melanoma lesions \>= 1 cm (Turnstile II)
• •Patients may have brain lesions which measure =\< 1 cm each (Turnstile II)
• •Patients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery (Turnstile II)
• •Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the patient agrees to continue to use a barrier method of contraception throughout the study such as: condom, diaphragm, hormonal, intrauterine device (IUD), or sponge plus spermicide; abstinence is an acceptable form of birth control (Turnstile II)
• •Pregnancy testing will be performed within 14 days prior to treatment (Turnstile II)
• •Clinical performance status of ECOG 0-2 within 14 days of lymphodepletion (Turnstile II)
• •Absolute neutrophil count greater than or equal to 1000/mm\^3 (Turnstile II)
• •Platelet count greater than or equal to 100,000/mm\^3 (Turnstile II)
• •Hemoglobin greater than or equal to 8.0 g/dl (Turnstile II)
• •Serum alanine transaminase (ALT) less than three times the upper limit of normal (Turnstile II)
• •Serum creatinine less than or equal to 1.6 mg/dl (Turnstile II)
• •Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's syndrome who must have a total bilirubin less than 3.0 mg/dl (Turnstile II)
• •A stress cardiac test (stress thallium, stress multigated acquisition \[MUGA\] scan, dobutamine echocardiogram or other stress test that will rule out cardiac ischemia) within 6 months of lymphodepletion (Turnstile II)
• •Forced expiratory volume in 1 second (FEV1) \> 65% of predicted within 6 months of lymphodepletion (Turnstile II) or
• •Forced vital capacity (FVC) \> 65% of predicted within 6 months of lymphodepletion (Turnstile II)
• •MRI/CT/PET of the brain within 30 days of lymphodepletion